The new anti-OLFML3 antibodies developed for therapeutic purposes inhibit tumor growth, tumor angiogenesis, lymphangiogenesis, pericyte coverage, and the expression of lymphangiogenic factors. This evidence concerns the gene OLFML3 and neoplasm.